Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of OBP-301 Plus Chemoradiotherapy in Locally Advanced Esophageal Cancer
jRCT1080225198Phase 1Terminated
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2020
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suratadenoturev in esophageal cancer, sponsored by Chugai Pharmaceutical Co., Ltd. Started May 2020; status: terminated.
02
Drugs
suratadenoturev
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1080225198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225198.